tirzepatide for cardiovascular disease outcomes trial results august 2025 compared with semaglutide and 10-year risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 Tirzepatide and the 10‐year predicted – SURPASS-CVOT Published: Large Trial Confirms

GLP-1 Success Starts with Dietitian Leadership It should come as no surprise that a large part of the success with incretin-based therapies like Ozempic, Wegovy, Mounjaro, and Zepboundstems from the effective integration of lifestyle modifications, particularly nutrition

In addition, GLP-1 can stimulate the epidermal growth factor (EGF), triggering the phosphatidylinositol-3 kinase (PI3K), which activates transcription factors associated with -cell growth while inhibiting those linked to -cell apoptosis (18)

Use a clean, fatty spot and rotate weekly

Most patients self-inject into the abdomen, thigh, or upper arm without difficulty after brief training

For this to be plausible, the market will look for: Strong adoption of the Wegovy pill in the U.S., with evidence that oral GLP1 can generate additional, rather than just cannibalized, demand

There may be more shortages if compounding pharmacies that have been filling the shortage gap have to stop producing it